Patents by Inventor Mohamad Morsey

Mohamad Morsey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus and Infectious Bursal Disease Virus Antigens
    Publication number: 20240123057
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.
    Type: Application
    Filed: February 1, 2023
    Publication date: April 18, 2024
    Applicant: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Ian Tarpey, Iwan Verstegen, Paulus Jacobus Antonius Sondermeijer, Paul Vermeij
  • ANTIBODIES AGAINST CANINE PD-1
    Publication number: 20240084004
    Abstract: The present invention discloses antibodies to canine PD-I that have specific sequences and a high binding affinity for canine PD-I. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: May 8, 2023
    Publication date: March 14, 2024
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • CANINIZED RAT ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR ALPHA
    Publication number: 20240002518
    Abstract: The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine EL-31 receptor alpha, and that can block the binding of canine IL-31 to canine EL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.
    Type: Application
    Filed: October 14, 2021
    Publication date: January 4, 2024
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Anasuya Saha
  • CANINIZED ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR ALPHA
    Publication number: 20230391879
    Abstract: The present invention provides caninized rat antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.
    Type: Application
    Filed: October 14, 2021
    Publication date: December 7, 2023
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Anasuya Saha
  • Bispecific Caninized Antibodies and Bispecific Binding Partners for Treating Atopic Dermatitis
    Publication number: 20230295289
    Abstract: The present invention provides compositions for treating canine atopic dermatitis that comprise a fusion protein that binds canine IL-22, a caninized anti-pruritic antibody, and a caninized anti-inflammatory antibody. The present invention further provides compositions that comprise a bispecific binding partners that comprises that fusion protein and a caninized anti-pruritic antibody or a caninized anti-inflammatory antibody, or alternatively, a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-inflammatory antibody, which in addition comprises a fusion protein that binds canine IL-22.
    Type: Application
    Filed: December 18, 2020
    Publication date: September 21, 2023
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Anasuya Saha
  • Bispecific Caninized Antibodies for Treating Atopic Dermatitis
    Publication number: 20230250177
    Abstract: The present invention provides compositions for treating canine atopic dermatitis that comprise a caninized anti-proliferative antibody, a caninized anti-pruritic antibody, and a caninized anti-inflammatory antibody. The present invention further relates to compositions that comprise a bispecific antibody that comprises a caninized anti -pruritic antibody and a caninized anti-proliferative antibody or alternatively a bispecific antibody comprising a caninized anti-pruritic antibody and a caninized anti-inflammatory antibody.
    Type: Application
    Filed: December 18, 2020
    Publication date: August 10, 2023
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Anasuya Saha
  • Antibodies against canine PD-1
    Patent number: 11680097
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: June 20, 2023
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Recombinant non-pathogenic Marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
    Patent number: 11596687
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: March 7, 2023
    Assignee: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Ian Tarpey, Iwan Verstegen, Paulus Jacobus Antonius Sondermeijer, Paul Vermeij
  • ANTIBODIES TO CANINE INTERLEUKIN-4 RECEPTOR ALPHA
    Publication number: 20230053131
    Abstract: The present invention provides antibodies to canine IL-4 receptor alpha that have a highbinding affinity for canine IL-4 receptor alpha, and that can block the binding of canine IL-4 and/or IL-13 to canine IL-4 receptor alpha. The present invention further relates to epitopes of canine IL-4 receptor alpha that bind to the antibodies to canine IL-4 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 16, 2023
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • CANINE INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODIES
    Publication number: 20230044037
    Abstract: The present invention provides antibodies to canine IL-4 receptor alpha that have a high binding affinity for canine IL-4 receptor alpha, and that can block the binding of canine IL-4 and/or IL-13 to canine IL-4 receptor alpha. The present invention further relates to epitopes of IL-4 receptor alpha that bind to the antibodies to canine IL-4 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 9, 2023
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • PD-L1 ANTIBODIES BINDING CANINE PD-L1
    Publication number: 20220389114
    Abstract: The present invention discloses antibodies including caninized antibodies against canine PD-L1 with specific properties. The present invention further relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes. The invention further discloses the use of the caninized anti-canine PD-LI antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: August 15, 2022
    Publication date: December 8, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • PD-L1 antibodies binding canine PD-L1
    Patent number: 11447561
    Abstract: The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: September 20, 2022
    Assignee: Intervet, Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Caninized Antibodies Against Canine CTLA-4
    Publication number: 20220251208
    Abstract: The present invention provides caninized murine antibodies against canine CTLA-4 that have specific sequences and a high binding affinity for canine CTLA-4. The present invention further provides epitopes of canine CTLA-4 for caninized murine antibodies against canine CTLA-4.5 The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals.
    Type: Application
    Filed: July 15, 2020
    Publication date: August 11, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • CANINIZED ANTIBODIES TO HUMAN CTLA-4
    Publication number: 20220251209
    Abstract: The present invention provides caninized anti-human CTLA-4 antibodies that have specific sequences and a high binding affinity for canine CTLA-4. The invention also relates to use of these antibodies in the treatment of cancer in canines and other companion animals.
    Type: Application
    Filed: July 15, 2020
    Publication date: August 11, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Caninized Antibodies
    Publication number: 20220204615
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: January 12, 2022
    Publication date: June 30, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus and Infectious Bursal Disease Virus Antigens
    Publication number: 20220125915
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.
    Type: Application
    Filed: June 15, 2017
    Publication date: April 28, 2022
    Applicant: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Ian Tarpey, Iwan Verstegen, Paulus Jacobus Antonius Sondermeijer, Paul Vermeij
  • RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING MULTIPLE HETEROLOGOUS ANTIGENS
    Publication number: 20220088187
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: Intervet Inc.
    Inventors: Stephanie M. Cook, Mohamad Morsey, Ian Tarpey
  • CANINIZED HUMAN ANTIBODIES TO HUMAN IL-4R ALPHA
    Publication number: 20220056143
    Abstract: The present invention provides caninized human anti-human IL-4R? antibodies that have specific sequences and a high binding affinity for canine IL-4R?. The invention also relates to use of these antibodies in the treatment of dogs against atopic dermatitis.
    Type: Application
    Filed: June 30, 2021
    Publication date: February 24, 2022
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang
  • Caninized antibodies
    Patent number: 11248047
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies against canine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 15, 2022
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Recombinant non-pathogenic Marek's Disease virus constructs encoding multiple heterologous antigens
    Patent number: 11229698
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: January 25, 2022
    Assignee: Intervet Inc.
    Inventors: Stephanie M. Cook, Mohamad Morsey, Ian Tarpey